<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01500863</url>
  </required_header>
  <id_info>
    <org_study_id>MAD-AB-ERA-2011</org_study_id>
    <nct_id>NCT01500863</nct_id>
  </id_info>
  <brief_title>Endometrial Receptivity After GnRH Agonist Triggering</brief_title>
  <acronym>ERAMAD</acronym>
  <official_title>Endometrial Receptivity After GnRH Agonist Triggering From Final Oocyte Maturation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IVI Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IVI Madrid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Conventional luteal phase support after human chorionic gonadotrophin (hCG) triggering in
      women undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) provides
      adequate pregnancy rates and live birth rates, but Ovarian hyperstimulation syndrome (OHSS)
      still occurs in 1-3% of the patients. If gonadotropin-releasing hormone agonist (GnRHa) are
      used instead of hCG, OHSS does not occur, but clinical results are somehow diminished.

      By testing different luteal support protocols on women undergoing GnRHa triggering, the
      investigators aim to find out which protocol resembles the most the gene expression profile
      observed after hCG triggering and conventional luteal phase support, in order to choose it as
      the most adequate in terms of endometrium receptivity and safety (OHSS incidence).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endometrial receptivity gene expression profile</measure>
    <time_frame>participants will be followed for the duration of the cycle, an expected average of 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of moderate/severe OHSS in all different treatment group</measure>
    <time_frame>participants will be followed for the duration of the cycle, an expected average of 4 weeks</time_frame>
    <description>Mild OHSS Grade 1, abdominal distension and discomfort Grade 2, features of grade 1 plus nausea, vomiting and/or diarrhea; ovaries are enlarged from 5 to 12 cm Moderate OHSS Grade 3, features of mild OHSS plus ultrasonic evidence of ascites Severe OHSS Grade 4, features of moderate OHSS plus evidence of ascites and/or hydrothorax and breathing difficulties Grade 5, all of the above, plus change in the blood volume, increased blood viscosity due to hemoconcentration, coagulation abnormality, and diminished renal perfusion and function</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Ovarian Hyperstimulation Syndrome</condition>
  <arm_group>
    <arm_group_label>hCG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Triptorelin 0.2mg s.c.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.2mg triptorelin plus estradiol/progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.2mg tripoterlin plus single bolus hCG 1500 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.2mg tripoterlin plus multiple boluses hCG 500 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.2mg tripoterlin plus multiple doses recLH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCG</intervention_name>
    <description>single shot of 6500 IU hCG s.c. at the time of triggering</description>
    <arm_group_label>hCG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triptorelin</intervention_name>
    <description>single shot of 0.2mg triptorelin s.c. at the time of triggering</description>
    <arm_group_label>Triptorelin 0.2mg s.c.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin, estradiol valerate, micronized vaginal progesterone</intervention_name>
    <description>4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU</description>
    <arm_group_label>0.2mg triptorelin plus estradiol/progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triptorelin, hCG</intervention_name>
    <description>single shot of 1500 IU hCG s.c. the day of OPU plus 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU</description>
    <arm_group_label>0.2mg tripoterlin plus single bolus hCG 1500 IU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triptorelin, hCG</intervention_name>
    <description>Multiple doses of 500 IU hCG (OPU, +4 and +7) and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU</description>
    <arm_group_label>0.2mg tripoterlin plus multiple boluses hCG 500 IU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triptorelin, recombinant LH</intervention_name>
    <description>300 IU recombinant LH every 48h and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU</description>
    <arm_group_label>0.2mg tripoterlin plus multiple doses recLH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Healthy oocyte donor women

          -  Aged 18-35 years

          -  With a menstrual cycle length of 26-35 days

          -  Normal ultrasound scan of uterus and ovaries

          -  Normal basal hormones

          -  No contraindication for controlled ovarian stimulation (COS)

          -  Willing to participate in the study and providing written informed consent.

        Exclusion Criteria:

          -  Subjects with current or previous history of an endocrine abnormality

          -  Subjects with an abnormal outcome of blood biochemistry or hematology

          -  Subjects with an abnormal cervical smear

          -  Subjects with a chronic disease

          -  Subjects with any relevant ovarian-, tubal- or uterine-pathology that could interfere
             with the COS treatment

          -  Pregnancy

          -  Subjects who had a previous history of ovarian hyperresponse or ovarian
             hyperstimulation syndrome (OHSS), polycystic ovary syndrome (PCOS) or a basal antral
             follicle count (AFC) of more than 20 on ultrasound (11 mm, both ovaries combined) .

          -  Previous low ovarian response to FSH or hMG treatment (i.e. cycle cancelled due to
             insufficient ovarian response or less than 6 oocytes obtained).

          -  A history of recurrent miscarriage,

          -  Smoking more than 10 cigarettes per day.

          -  Not willing to comply with study procedures
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfonso Bermejo, MD</last_name>
    <role>Study Director</role>
    <affiliation>IVI Madrid</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Valenciano de Infertilidad</name>
      <address>
        <city>Madrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2011</study_first_submitted>
  <study_first_submitted_qc>December 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2011</study_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endometrial receptivity</keyword>
  <keyword>gene arrays</keyword>
  <keyword>agonist triggering</keyword>
  <keyword>Endometrial gene expression</keyword>
  <keyword>OHSS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Deslorelin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

